Case Studies / Business Development

_

IN-LICENSING DILIGENCE
A mid-sized pharmaceutical company based on the East Coast commissioned Aquest to conduct a full US commercial assessment of a novel phase 3 program being evaluated for in-licensing. Work included primary market research (of KOL’s, community physicians, nurses and relevant payers), secondary data gathering and analysis, competitive assessment, forecast modeling, and analysis of prescription trends in the market. Aquest represented the client in early meetings with the prospective partner and ultimately uncovered an overlooked aspect of the payer value proposition that significantly impacted valuation.
EX-US OPPORTUNITY ASSESSMENT
A mid-sized pharmaceutical company decided to take a fresh look at potential agents to in-license. Their question was simple yet challenging: are there any attractive opportunities among compounds currently marketed in ex-US territories that have never been reviewed by the FDA? Aquest built a sophisticated data gathering and screening tool (keying off such value drivers as strength of clinical evidence, therapeutic area attractiveness, commercial potential, regulatory pathway risk, and IP status). A process that started with over 10,000 compounds resulted in a prioritized list of 10 promising agents, several of which were selected for more intensive diligence.
IN-LICENSING DILIGENCE
A public biopharmaceutical company with approved products commissioned Aquest to evaluate a global prescription brand to potentially acquire. Working with the head of commercialization on this highly confidential project, Aquest conducted a thorough investigation and analysis of the patient population and growth drivers, opinion leader perspectives, in-depth competitive analysis, potential development pathways, product sales and projections by patient segment and region, profit analysis, risk analysis and organizational requirements to support and grow the brand. The results were presented to the executive team and board (the highly confidential nature of this project prevents us from divulging the outcome).
DRUG DELIVERY TECHNOLOGY ASSESSMENT
A drug delivery company with an innovative technology platform sought assistance in identifying new and commercially promising small molecules and proteins to integrate with their technology. Aquest worked closely with an internal client team to develop a screening methodology based on several key determinants of value (technical feasibility, clinical development cost and timelines, regulatory risk, commercial potential, loss of exclusivity, and partnerability) and generated a prioritized list of candidates the client used to defend their investment decisions at the next board meeting.
IN-LICENSING DILIGENCE
A mid-sized pharmaceutical company based on the East Coast commissioned Aquest to conduct a full US commercial assessment of a novel phase 3 program being evaluated for in-licensing. Work included primary market research (of KOL’s, community physicians, nurses and relevant payers), secondary data gathering and analysis, competitive assessment, forecast modeling, and analysis of prescription trends in the market. Aquest represented the client in early meetings with the prospective partner and ultimately uncovered an overlooked aspect of the payer value proposition that significantly impacted valuation.
EX-US OPPORTUNITY ASSESSMENT
A mid-sized pharmaceutical company decided to take a fresh look at potential agents to in-license. Their question was simple yet challenging: are there any attractive opportunities among compounds currently marketed in ex-US territories that have never been reviewed by the FDA? Aquest built a sophisticated data gathering and screening tool (keying off such value drivers as strength of clinical evidence, therapeutic area attractiveness, commercial potential, regulatory pathway risk, and IP status). A process that started with over 10,000 compounds resulted in a prioritized list of 10 promising agents, several of which were selected for more intensive diligence.
IN-LICENSING DILIGENCE
A public biopharmaceutical company with approved products commissioned Aquest to evaluate a global prescription brand to potentially acquire. Working with the head of commercialization on this highly confidential project, Aquest conducted a thorough investigation and analysis of the patient population and growth drivers, opinion leader perspectives, in-depth competitive analysis, potential development pathways, product sales and projections by patient segment and region, profit analysis, risk analysis and organizational requirements to support and grow the brand. The results were presented to the executive team and board (the highly confidential nature of this project prevents us from divulging the outcome).
DRUG DELIVERY TECHNOLOGY ASSESSMENT
A drug delivery company with an innovative technology platform sought assistance in identifying new and commercially promising small molecules and proteins to integrate with their technology. Aquest worked closely with an internal client team to develop a screening methodology based on several key determinants of value (technical feasibility, clinical development cost and timelines, regulatory risk, commercial potential, loss of exclusivity, and partnerability) and generated a prioritized list of candidates the client used to defend their investment decisions at the next board meeting.